On ECHEMI
Home > Drugs > Guosen Pharmaceutical Co., Ltd.
Guosen Pharmaceutical Co., Ltd.
  • Founded in:

    2005-02-22
  • Country:

    China China
  • Address:

    No. 669, Changjiang West Road, High-tech Zone, Hefei City, Anhui Province
  • Tax NO.:

    91340000771133813K
  • Registered Funds:

    89.66 million yuan
  • Email:

Related Drugs
Levofloxacin Lactate Sodium Chloride Injection
Levofloxacin lactate.
Name Description Content CAS NO. Registered Holders
LEVOFLOXACIN LACTATE

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

More

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

294662-18-3 11
Levofloxacin Lactate Sodium Chloride Injection
Levofloxacin lactate.
Name Description Content CAS NO. Registered Holders
LEVOFLOXACIN LACTATE

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

More

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

294662-18-3 11
Curcuma Oil and Glucose Injection
The main ingredient of this product is zedoary oil.
Name Description Content CAS NO. Registered Holders
Curcuma oil

It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.

More

It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.

8024-37-1 1
Xuesetong dispersible tablets
The effective part, notoginseng glycosides, extracted from Panax notoginseng, a plant of the genus Panax in the Araliaceae family, is notoginseng total glycosides, which mainly include ginsenoside R, ginsenoside Rb, and notoginsenoside R.
Name Description Content CAS NO. Registered Holders
Notoginseng triterpenes

Dilate coronary and peripheral blood vessels, reduce peripheral resistance, slow heart rate, reduce and lower myocardial oxygen consumption, increase myocardial perfusion, increase cerebral blood flow, improve myocardial and cerebral ischemia; inhibit platelet aggregation, reduce blood viscosity, inhibit thrombosis; lower blood lipids, resist fatigue, tolerate hypoxia, improve and enhance macrophage function.

More

Dilate coronary and peripheral blood vessels, reduce peripheral resistance, slow heart rate, reduce and lower myocardial oxygen consumption, increase myocardial perfusion, increase cerebral blood flow, improve myocardial and cerebral ischemia; inhibit platelet aggregation, reduce blood viscosity, inhibit thrombosis; lower blood lipids, resist fatigue, tolerate hypoxia, improve and enhance macrophage function.

88105-29-7 0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.